NCT05382585 Newer Therapeutic Targets in Head and Neck Cancers
| NCT ID | NCT05382585 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Banaras Hindu University |
| Condition | Head Neck Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2017-04-01 |
| Primary Completion | 2027-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes: 1. cellular survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); 2. cell-cycle control (e.g., CDKN2A and CCND1); 3. cellular differentiation (e.g., NOTCH1); and 4. Adhesion and invasion signaling (e.g., FAT1).7 TP53, EGFR, PIK3CA, CDKN2A, CCND1, and MET participate in several common signaling pathways. Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known
Eligibility Criteria
Inclusion Criteria: * Histologically proven cases of primary head and neck cancers. Exclusion Criteria: * Patients under 18 years of age * Pregnant and lactating women * Multiple cancers or patients with cancer of other sites.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.